Pathophysiology of thyroid-associated orbitopathy

被引:26
|
作者
Lee, Alan Chun Hong [1 ,2 ,3 ]
Kahaly, George J. [2 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, LKS Fac Med, Dept Med,Div Endocrinol & Metab, Hong Kong, Peoples R China
[2] Johannes Gutenberg Univ Mainz, Dept Med 1, Med Ctr, D-55101 Mainz, Germany
[3] Queen Mary Hosp, A1 Med Off, 102 Pokfulam Rd, Hong Kong, Peoples R China
关键词
thyroid-associated orbitopathy; orbital fibroblasts; T helper 17; thyroid stimulating hormone receptor; insulin-like growth factor-1 receptor; crosstalk; GRAVES ORBITOPATHY; STIMULATING IMMUNOGLOBULINS; ORBITAL FIBROBLASTS; GROWTH-FACTOR; EYE DISEASE; TH17; CELLS; T-CELLS; MANAGEMENT; RELEVANCE; PATHOGENESIS;
D O I
10.1016/j.beem.2022.101620
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid-associated orbitopathy, the most common extrathyroidal manifestation of Graves' disease, is characterized by orbital in-flammatory infiltration and activation of orbital fibroblasts, which mediates de novo adipogenesis, excessive production of hyalur-onan, myofibroblast differentiation and ultimately tissue fibrosis. Interactions among T cells, B cells, and orbital fibroblasts result in their activation and perpetuation of orbital inflammation as well as tissue remodelling. T helper 17 cells belong to a newly identified pathogenic CD4 thorn T cell subset which possesses prominent pro -inflammatory and profibrotic capabilities. Thyroid stimulating hormone receptor/insulin-like growth factor-1 receptor crosstalk and the downstream signalling pathways of both receptors represent the major mechanisms leading to activation of orbital fibroblasts. Thyroid stimulating hormone receptor autoantibody is the disease specific biomarker of great clinical relevance and utility. There is growing evidence that oxidative stress, gut microbiome and epigenetics also play a role in the pathogenesis and their manipulation may represent novel therapeutic strategies.(c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Thyroid-Associated Orbitopathy
    Tarabishy, Ahmad B.
    Lewis, Criag D.
    Perry, Julian D.
    OPHTHALMOLOGY, 2010, 117 (09) : 1864 - 1864
  • [2] Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management
    Bhatt, Rina
    Nelson, Christine C.
    Douglas, Raymond S.
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2011, 25 (01) : 15 - 20
  • [3] The immunogenetics of thyroid-associated orbitopathy
    Weetman, AP
    Hunt, PJ
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S149 - S151
  • [4] Imaging in thyroid-associated orbitopathy
    Kahaly, GJ
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2001, 145 (02) : 107 - 118
  • [5] Radiotherapy for thyroid-associated orbitopathy
    Kahaly, GJ
    Roesler, HP
    Kutzner, J
    Pitz, S
    Müller-Forell, W
    Beyer, J
    Mann, W
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S201 - S207
  • [6] PSEUDORETRACTION OF THE EYELID IN THYROID-ASSOCIATED ORBITOPATHY
    GONNERING, RS
    ARCHIVES OF OPHTHALMOLOGY, 1988, 106 (08) : 1078 - 1080
  • [7] Choroidal thickness in thyroid-associated orbitopathy
    Lai, Frank H. P.
    Iao, Tiara W. U.
    Ng, Danny S. C.
    Young, Alvin L.
    Leung, Joy
    Au, Alvin
    Ko, Simon T. C.
    Chong, Kelvin K. L.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 (07): : 918 - 924
  • [8] Ophthalmic management of thyroid-associated orbitopathy
    Guthoff, R
    Schittkowski, M
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S175 - S176
  • [9] Glabellar rhytids in thyroid-associated orbitopathy
    Saks, ND
    Burnstine, MA
    Putterman, AM
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2001, 17 (02): : 91 - 95
  • [10] Medical treatment of thyroid-associated orbitopathy
    Prummel, MF
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S198 - S200